Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland

References

• Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
   PubMed Web of Science ®Google Scholar
• Statistics Finland. Kuolleet kuolemansyyn, iän ja sukupuolen mukaan 1986–2006, koko maa ja maakunnat
   Google Scholar
• NAM, SII. Finnish Statistics on Medicines. Helsinki: Edita Prima Oy, 2007
   Google Scholar
• Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-19
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007;115:e69-171
   PubMed Web of Science ®Google Scholar
• CTT. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. Br Med J 1994;309:23-7
   PubMed Web of Science ®Google Scholar
• Käypä Hoito. Dyslipidemiat. Helsinki: Suomalainen Lääkäriseura Duodecim, 2009
   Google Scholar
• Laatikainen T, Tapanainen H, Alfthan G, et al. FINRISKI 2002: Tutkimuksen toteutus ja tulokset 1: Perusraportti. Helsinki: Kansanterveyslaitoksen julkaisuja, 2003;B7
   Google Scholar
• Väistö T, Pajunen P, Jousilahti P, et al. Valtimotautitapahtumien riskiryhmään kuuluvien ja kuulumattomien kolesterolitasot FINRISKI 2002 -tutkimuksessa. Finnish Med J 2005;60:389-94
   Google Scholar
• Strandberg T, Vanhanen H. Dyslipidemian hoitotavoitteiden saavuttaminen 2000 ja 2005 – Onko edistystä tapahtunut. Finnish Med J 2006;61:4689-94
   Google Scholar
• Saarni SI, Harkanen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403-14
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423-9
   PubMed Web of Science ®Google Scholar
• Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(Suppl. 3):49-61
   PubMed Web of Science ®Google Scholar
• Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004;22(Suppl. 3):37-48
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;12:293-8
   Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
   PubMed Web of Science ®Google Scholar
• Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571-8
   PubMed Web of Science ®Google Scholar
• Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005;59:619-27
   PubMed Web of Science ®Google Scholar
• Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327-32
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95
   PubMed Web of Science ®Google Scholar
• Masana L, Mata P, Gagne C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005;27:174-84
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries. Clin Ther 2008;30:1508-23
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511
   PubMed Web of Science ®Google Scholar
• Kattainen E, Sintonen H, Kettunen R, et al. Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients: 1-year follow-up. Int J Technol Assess Health Care 2005;21:172-9
   PubMed Web of Science ®Google Scholar
• Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. Helsinki: Stakes, 2008
   Google Scholar
• Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. Circulation 1999;99:3028-35
   PubMed Web of Science ®Google Scholar
• Kattainen E. A Longitudinal Research of the Coronary Artery Bypass Grafting (CABG) and Percutaneous Transluminal Coronary Artery Angioplasty (PTCA) Patients’ Health-Related Quality of Life. Kuopio: University of Kuopio, 2004
   Google Scholar
• Hallinen T, Martikainen JA, Soini EJ, et al. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006;22:683-92
   PubMed Web of Science ®Google Scholar
• Kangas T. Diabeetikkojen Terveyspalvelut Ja Niiden Kustannukset – Helsinkiläisten diabeetikkojen verrokkikontrolloitu poikkileikkaustutkimus. Helsinki: Kansaneläkelaitos, 2002
   Google Scholar
• Häkkinen U, Idänpään-Heikkilä U, Keskimäki I, et al. PERFECT – Sydäninfarkti: Sydäninfarktin hoito, kustannukset ja vaikuttavuus. Helsinki: Stakes, 2007
   Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87
   PubMed Web of Science ®Google Scholar
• Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886-97
   PubMed Web of Science ®Google Scholar
• Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823-32
   PubMed Web of Science ®Google Scholar
• Martikainen JA, Ottelin AM, Kiviniemi V, et al. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach. Eur J Cardiovasc Prev Rehabil 2007;14:265-72
   PubMed Web of Science ®Google Scholar
• Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics 2006;24:815-30
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-9
   PubMed Web of Science ®Google Scholar
• Alemao E, Yin D, Sintonen H, et al. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: The national FINRISK study. Am J Cardiovasc Drugs 2006;6:349-55
   PubMedGoogle Scholar